A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 50
Summary
- Conditions
- BRAF Mutant Colorectal Cancer
- Cervical Squamous Cell Cancer
- Esophageal Squamous Cell Cancer
- Head and Neck Squamous Cell Cancer
- Lung Squamous Cell Cancer
- Melanoma
- Pancreatic Cancer
- Triple -Negative Breast Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01351103
- Collaborators
- Not Provided
- Investigators
- Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals